Clinical ResearchCoronaryRandomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial
Coronary
Under an Elsevier user license
open archive
Key Words
drug-eluting stent(s)
long-term follow-up
probucol
randomized controlled trial
sirolimus
zotarolimus
Abbreviations and Acronyms
CI
confidence interval
CK
creatine kinase
DES
drug-eluting stent(s)
HR
hazard ratio
MI
myocardial infarction
ULN
upper limit of normal
Cited by (0)
Funding for this study was provided in part by the Bavarian Research Foundation (BFS-ISAR Aktenzeichen AZ: 504/02 and BFS-DES Aktenzeichen AZ: 668/05) and by the European Union FP7 (PRESTIGE 260309). Dr. Kastrati has patent applications related to drug-eluting stent coatings. Dr. Byrne has received lecture fees from B. Braun Melsungen AG, Biotronik, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.